Prednisolone-Sparing Regimens in Combination Chemotherapy for Lymphoma: Toxicity and Response Outcomes
DOI:
https://doi.org/10.5281/zenodo.22644228Keywords:
prednisolone-sparing chemotherapy, lymphoma toxicity, R-miniCHOP, corticosteroid-related adverse effects, elderly Hodgkin lymphoma treatmentAbstract
Background: Corticosteroids such as prednisone and prednisolone are integral components of combination chemotherapy for
Hodgkin and non-Hodgkin lymphoma, but their inclusion is associated with hyperglycemia, myopathy, opportunistic infection, and
other toxicities that disproportionately affect older and frailer patients. Objective: This narrative review synthesizes published
evidence on prednisolone-sparing and steroid-attenuated combination chemotherapy regimens for lymphoma, focusing on their
toxicity profiles and response/survival outcomes. Methods: Primary clinical trial reports, retrospective cohort studies, and
mechanistic reviews addressing corticosteroid dose modification in lymphoma chemotherapy, including R-CHOP, R-miniCHOP,
dose-adjusted EPOCH-R, VEPEMB, and PVAG, were identified and synthesized thematically. Findings: Dose-attenuated regimens
such as R-miniCHOP achieved 2-year overall survival of 59% in patients over 80 years old with diffuse large B-cell lymphoma, while
the reduced-intensity PVAG regimen achieved a 78% complete remission rate and 66% 3-year overall survival in elderly Hodgkin
lymphoma, with treatment-related mortality below 10% in both settings despite substantial grade 3-4 toxicity.
Corticosteroid-attributable hyperglycemia, myopathy, and opportunistic infection persisted even in attenuated regimens, and dose
modification was consistently implemented alongside parallel changes to anthracycline dose, cycle length, or antibody use,
precluding isolation of the corticosteroid contribution alone. Conclusions: Prednisolone-sparing and steroid-attenuated regimens
preserve meaningful anti-lymphoma activity while reducing, but not eliminating, corticosteroid-related toxicity, supporting their
role in fitness- and frailty-stratified treatment algorithms for older or less fit lymphoma patients.
References
Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R (2004) Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death & Differentiation, 11(S1):S45-S55, DOI:10.1038/sj.cdd.4401456.
Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, Reyes F, Lederlin P, Gisselbrecht C (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346(4):235-242, DOI:10.1056/NEJMoa011795.
Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM (1997) Steroid myopathy in cancer patients. Neurology, 48(5):1234-1238, DOI:10.1212/WNL.48.5.1234.
Kristjanson M, Lambert P, Decker KM, Bruin S, Tingey E, Skrabek P (2023) Steroid-Induced Hyperglycemia and Its Effect on Outcomes of R-CHOP Chemotherapy for Diffuse Large B-Cell Lymphoma. Current Oncology, 30(12):10142-10151, DOI:10.3390/curroncol30120738.
Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, Andre M, Fournier M, Gaulard P, Tilly H (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. The Lancet Oncology, 12(5):460-468, DOI:10.1016/S1470-2045(11)70069-9.
Rodday AM, Hahn T, Kumar AJ, Lindenauer PK, Friedberg JW, Evens AM, Parsons SK (2020) First-line treatment in older patients with Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results (SEER)-Medicare population-based study. British Journal of Haematology, 190(2):222-235, DOI:10.1111/bjh.16525.
Oberic L, Peyrade F, Puyade M, Bonnet C, Dartigues-Cuilleres P, Fabiani B, Ruminy P, Maisonneuve H, Abraham J, Thieblemont C, Feugier P, Salles G, Bijou F, Pica GM, Damaj G, Haioun C, Casasnovas RO, Farhat H, Le Calloch R, Waultier-Rascalou A, Malak S, Paget J, Gat E, Tilly H, Jardin F (2021) Subcutaneous Rituximab-MiniCHOP Compared With Subcutaneous Rituximab-MiniCHOP Plus Lenalidomide in Diffuse Large B-Cell Lymphoma for Patients Age 80 Years or Older. Journal of Clinical Oncology, 39(11):1203-1213, DOI:10.1200/JCO.20.02666.
Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, Reiser M, Nickenig C, Clemens M, Peter N, Bokemeyer C, Eimermacher H, Ho A, Hoffmann M, Mertelsmann R, Trumper L, Balleisen L, Liersch R, Metzner B, Hartmann F, Glass B, Poeschel V, Schmitz N, Ruebe C, Feller AC, Loeffler M (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). The Lancet Oncology, 9(2):105-116, DOI:10.1016/S1470-2045(08)70002-0.
Levis A, Anselmo AP, Ambrosetti A, Adamo F, Bertini M, Cavalieri E, Gavarotti P, Genua A, Liberati M, Pavone V, Pietrasanta D, Ricetti MM, Scalabrini DR, Salvi F, Vitolo U, Angelucci E, Boccadoro M, Gallo E, Mandelli F (2004) VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Annals of Oncology, 15(1):123-128, DOI:10.1093/annonc/mdh012.
Boll B, Bredenfeld H, Gorgen H, Halbsguth T, Eich HT, Soekler M, Markova J, Keller U, Graeven U, Kremers S, Geissler M, Trenn G, Fuchs M, von Tresckow B, Eichenauer DA, Borchmann P, Engert A (2011) Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood, 118(24):6292-6298, DOI:10.1182/blood-2011-07-368167.
Zallio F, Tamiazzo S, Monagheddu C, Merli F, Ilariucci F, Stelitano C, Liberati AM, Mannina D, Vitolo U, Angelucci E, Rota Scalabrini D, Vallisa D, Bellei M, Bari A, Ciccone G, Salvi F, Levis A (2016) Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL). British Journal of Haematology, 172(6):879-888, DOI:10.1111/bjh.13904.
Hormigo-Sanchez AI, Lopez-Garcia A, Mahillo-Fernandez I, Askari E, Morillo D, Perez-Saez MA, Riesco M, Urrutia C, Martinez-Peromingo FJ, Cordoba R, Gonzalez-Montalvo JI (2023) Frailty assessment to individualize treatment in older patients with lymphoma. European Geriatric Medicine, 14(6):1393-1402, DOI:10.1007/s41999-023-00870-2.
Lugtenburg PJ, Mutsaers PGNJ (2023) How I treat older patients with DLBCL in the frontline setting. Blood, 141(21):2566-2575, DOI:10.1182/blood.2020008239.
Lamar ZS, Dothard A, Kennedy L, Isom S, Robinson M, Vaidya R, Hurd D, McClain D, Lesser G (2018) Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leukemia & Lymphoma, 59(8):1871-1877, DOI:10.1080/10428194.2017.1410889.
Hardak E, Oren I, Dann EJ, Yigla M, Faibish T, Rowe JM, Avivi I (2012) The Increased Risk for Pneumocystis Pneumonia in Patients Receiving Rituximab-CHOP-14 Can Be Prevented by the Administration of Trimethoprim/Sulfamethoxazole: A Single-Center Experience. Acta Haematologica, 127(2):110-114, DOI:10.1159/000334113.
Cunningham D, Hawkes EA, Jack A, Qian W, Smith P, Mouncey P, Pocock C, Ardeshna KM, Radford JA, McMillan A, Davies J, Turner D, Kruger A, Johnson P, Gambell J, Linch D (2013) Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles. The Lancet, 381(9880):1817-1826, DOI:10.1016/S0140-6736(13)60313-X.
Bartlett NL, Wilson WH, Jung SH, Hsi ED, Maurer MJ, Pederson LD, Polley MYC, Pitcher BN, Cheson BD, Kahl BS, Friedberg JW, Staudt LM, Wagner-Johnston ND, Blum KA, Abramson JS, Reddy NM, Winter JN, Chang JE, Gopal AK, Chadburn A, Mathew S, Fisher RI, Richards KL, Schoder H, Zelenetz AD, Leonard JP (2019) Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303. Journal of Clinical Oncology, 37(21):1790-1799, DOI:10.1200/JCO.18.01994.
Bartlett NL (2020) Approaches to aggressive B-cell lymphomas in less fit patients. Hematology, 2020(1):140-147, DOI:10.1182/hematology.2020000099.
